Volante Marco, Rindi Guido, Papotti Mauro
Department of Clinical and Biological Sciences, University of Turin and San Luigi Hospital, Regione Gonzole10, 10043 Orbassano-Torino, Italy.
Virchows Arch. 2006 Nov;449(5):499-506. doi: 10.1007/s00428-006-0306-2. Epub 2006 Oct 11.
Terms such as "mixed endocrine-exocrine carcinoma" (MEEC) and "adenocarcinoma with neuroendocrine (NE) differentiation" (ADC-NE) identify tumours belonging to the spectrum of neoplasms with divergent exocrine and (neuro)endocrine differentiation. These tumours display variable quantitative extent of the two components, potentially ranging from 1 to 99%, and variable structural patterns, ranging from single scattered NE cells to a well-defined NE tumour cell population organized in organoid, trabecular or solid growth patterns. In the present report, the grey zone of tumours/carcinomas with mixed NE and non-NE features is explored for various organs. From a practical point of view, MEECs differ from carcinomas with focal NE differentiation by (1) the extension of each component (more than 30%) and (2) the structural pattern of the NE component, either organoid for well-differentiated or solid/diffuse for poorly differentiated cases. In MEECs, the most aggressive cell population drives the clinical behaviour. Conversely, ADC-NE generally do not show a different clinical outcome, compared to the corresponding conventional forms, except for prostatic adenocarcinoma, in which NE cells are a negative prognostic factor. The recognition of MEECs may be of relevance for a targeted therapeutic strategy, foreseeing the use of biotherapies similar to those proposed for pure NE tumours.
“混合性内分泌-外分泌癌”(MEEC)和“伴有神经内分泌(NE)分化的腺癌”(ADC-NE)等术语用于识别属于具有不同外分泌和(神经)内分泌分化的肿瘤谱系的肿瘤。这些肿瘤显示出两种成分的不同数量范围,可能从1%到99%不等,以及不同的结构模式,从单个散在的NE细胞到以类器官、小梁或实性生长模式组织的明确的NE肿瘤细胞群体。在本报告中,探讨了具有混合NE和非NE特征的肿瘤/癌在各个器官中的灰色地带。从实际角度来看,MEEC与具有局灶性NE分化的癌的区别在于:(1)每种成分的范围(超过30%);(2)NE成分的结构模式,分化良好的为类器官型,分化差的为实性/弥漫型。在MEEC中,最具侵袭性的细胞群体决定临床行为。相反,与相应的传统形式相比,ADC-NE通常不显示不同的临床结果,但前列腺腺癌除外,其中NE细胞是一个负性预后因素。识别MEEC可能与靶向治疗策略相关,可预见使用类似于针对纯NE肿瘤提出的生物疗法。